Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Huperzine A


  • Brand : BIOFRON

  • Catalogue Number : AV-P11369

  • Specification : 98%

  • CAS number : 102518-79-6

  • Formula : C15H18N2O

  • Molecular Weight : 242.32

  • PUBCHEM ID : 449069

  • Volume : 25mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight



White crystalline powder

Botanical Source

Lycopodium serratum Thunb.

Structure Type



Standards;Natural Pytochemical;API



5-Amino-1,2-dihydro-3H-pyrazol-3-one/(?)-Huperzine A/(?)-Selagine/(-)-Huperzine A/3-Amino-5-pyrazolone/3-Amino-1H-pyrazol-5-ol/3H-Pyrazol-3-one, 5-amino-1,2-dihydro-/Huperzine A




Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD). IC50 value:Target: AChEHuperzine A exhibited protective effects against d-gal-induced hepatotoxicity and inflamm-aging by inhibiting AChE activity and via the activation of the cholinergic anti-inflammatory pathway. The huperzine A mechanism might be involved in the inhibition of DAMPs-mediated NF-κB nuclear localization and activation. Huperzine A is a potential therapeutic agent for Alzheimer's disease.


1.6±0.1 g/cm3


Methanol; Chloroform; DMSO

Flash Point

243.8±23.2 °C

Boiling Point

479.5±25.0 °C at 760 mmHg

Melting Point



InChl Key

WGK Germany


HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:102518-79-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Acetylcholinesterase inhibitors are regarded as promising therapeutic agents to treat addiction. The current study aimed to examine the effects of huperzine A, a cholinesterase inhibitor, on behavioral sensitization induced by repeated morphine administration and relapse induced by contextual conditioning. The present study also assessed whether the state-dependency hypothesis may explain the results. Adult rats were divided into four groups (n=8) and intraperitoneally injected with 0.2, 0.3 or 0.4 mg/kg huperzine A or saline (1 ml/kg, control), for 5 days. The effect of repeated huperzine A administration alone on locomotor activity was assessed. For the experiments that analyzed the development of morphine-induced sensitization, 40 rats were divided into five groups (n=8): Saline+Saline, Saline+Morphine, 0.2, 0.3 and 0.4 mg/kg huperzine A+Morphine. Following a withdrawal period of 7 days, all animals were administered saline or morphine, as appropriate. To test the state-dependency hypothesis, the rats in the Saline+Morphine group were injected with saline and morphine, while the other three groups were administered different doses of huperzine A and morphine. To examine the effect of huperzine A on the expression of morphine-induced sensitization, the rats in huperzine A+Morphine groups were injected with appropriate concentrations of huperzine A, and morphine. The current results indicated that the administration of huperzine A alone did not affect locomotor activity, while higher doses of huperzine A inhibited the addictive behavior induced by morphine at the development phase. Additionally, huperzine A administration during the expression phase of morphine sensitization did not inhibit the relapse induced by administration of saline. Furthermore, 0.4 mg/kg huperzine A inhibited the expression of morphine-induced behavioral sensitization. Therefore, the results of the current study do not support the state-dependency hypothesis.


behavioral sensitization; cholinesterase inhibitor; huperzine A; morphine.


Huperzine A Inhibits Immediate Addictive Behavior but Not Behavioral Sensitization Following Repeated Morphine Administration in Rats


Jinling Sun 1 , Lin Tian 1 , Ruisi Cui 1 , Xinwang Li 1

Publish date

2017 Apr




Alzheimer’s disease (AD) is the most frequent cause of dementia. Besides cognitive deterioration, patients with AD are prone to seizures – more than 20% of patients diagnosed with AD experience at least one unprovoked seizure and up to 7% have recurrent seizures. Although available antiepileptic drugs (AEDs) may suppress seizures in patients with AD, they may also worsen cognitive dysfunction and increase the risk of falls. On the basis of preclinical studies, we hypothesize that Huperzine A (HupA), a safe and potent acetylcholinesterase (AChE) inhibitor with potentially disease-modifying qualities in AD, may have a realistic role as an anticonvulsant in AD.


Acetylcholinesterase; Alzheimer’s disease; Antiepileptic; Huperzine A; Nicotinic; Seizure; ppTMS.


Huperzine A: A Promising Anticonvulsant, Disease Modifying, and Memory Enhancing Treatment Option in Alzheimer's Disease


Ugur Damar 1 , Roman Gersner 1 , Joshua T Johnstone 2 , Steven Schachter 3 , Alexander Rotenberg 4

Publish date

2017 Feb




Background: Alzheimer’s Disease (AD) is associated with cognitive decline due to various pathological mechanisms. There are several acetylcholinesterase inhibitor compounds which can improve cognition, but Huperzine-A is a natural sesquiterpene alkaloid extracted from Chinese herb (Huperzia Serrata) which has rapid action.
Methods: Double blind study was conducted. Participants included 50 patients with AD and 50 healthy individuals. Patients were recruited from Civil and BV hospital Bahawalpur and Nishter hospital Multan, Pakistan during May 2017 until February 2018 who were stable on Huperzine-A medication. Patients were tested twice. First, at the time of diagnosis to determine baseline scores. Second, post eight weeks of Huperzine-A treatment. Healthy individuals had single testing session. Participants completed Addenbrooke’s Cognitive Examination and Trail Making Test.
Results: Patients with AD showed cognitive and task switching deficits in contrast with healthy individuals. There was significant improvement in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance.
Conclusion: Huperzine-A is effective in reducing cognitive and task switching deficits in patients with AD.


Acetylcholinesterase inhibitor; Alzheimer's disease; Cognition; Huperzine-A.


Huperzine-A Response to Cognitive Impairment and Task Switching Deficits in Patients With Alzheimer's Disease


Amara Gul 1 , Jehan Bakht 2 , Farah Mehmood 3

Publish date

2018 Sep 7